Basil Rigas

Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress.

The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia.

Development of novel agents based on nitric oxide for the control of colon cancer.

The novel phenylester anticancer compounds: Study of a derivative of aspirin (phoshoaspirin).

NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action.

A potentiometric protein sensor built with surface molecular imprinting method.

NO-Donating NSAIDs, PPARdelta, and Cancer: Does PPARdelta Contribute to Colon Carcinogenesis?

NO-donating aspirin inhibits angiogenesis by suppressing VEGF expression in HT-29 human colon cancer mouse xenografts.

Nitric oxide-donating aspirin inhibits the growth of pancreatic cancer cells through redox-dependent signaling.

Pharmacokinetic and pharmacodynamic study of NO-donating aspirin in F344 rats.

The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents.

Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death.

Food components, alternative medicine, and cancer: progress and promise.

Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect.

Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-CATENIN pathway and nonsteroidal antiinflammatory drugs.

The differential cell signaling effects of two positional isomers of the anticancer NO-donating aspirin.

Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo.

Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.

Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect.

Protein nitration and nitrosylation by NO-donating aspirin in colon cancer cells: Relevance to its mechanism of action.

Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models.

Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.

Oxidative stress mediates through apoptosis the anticancer effect of phospho-nonsteroidal anti-inflammatory drugs: implications for the role of oxidative stress in the action of anticancer agents.

Structure-activity relationship study of novel anticancer aspirin-based compounds.

Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds.

Sterically stabilized liposomes incorporating the novel anticancer agent phospho-ibuprofen (MDC-917): preparation, characterization, and in vitro/in vivo evaluation.

Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity.

Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system.

Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents.

Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety.

Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts.

Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles.

In vitro and in vivo metabolic studies of phospho-aspirin (MDC-22).

Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer.

MC-12, an annexin A1-based peptide, is effective in the treatment of experimental colitis.

Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives.

Platinum folate nanoparticles toxicity: cancer vs. normal cells.

The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies.

Comparative in vitro metabolism of phospho-tyrosol-indomethacin by mice, rats and humans.

Topically applied phospho-sulindac hydrogel is efficacious and safe in the treatment of experimental arthritis in rats.

Aerosol administration of phospho-sulindac inhibits lung tumorigenesis.

Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice.

Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics.

A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice.

Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate.

Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress.

The in vitro metabolism of phospho-sulindac amide, a novel potential anticancer agent.

Pegylation improves the pharmacokinetics and bioavailability of small-molecule drugs hydrolyzable by esterases: a study of phospho-Ibuprofen.

A novel ibuprofen derivative with anti-lung cancer properties: synthesis, formulation, pharmacokinetic and efficacy studies.

Phospho-aspirin-2 (MDC-22) inhibits estrogen receptor positive breast cancer growth both in vitro and in vivo by a redox-dependent effect.

Phospho-NSAIDs have enhanced efficacy in mice lacking plasma carboxylesterase: implications for their clinical pharmacology.

Repurposing the antipsychotic trifluoperazine as an antimetastasis agent.

The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimism.

Altered Interactions between the Gut Microbiome and Colonic Mucosa Precede Polyposis in APCMin/+ Mice.

NSAIDs and Colorectal Cancer Control: Promise and Challenges.

The novel agent phospho-glycerol-ibuprofen-amide (MDC-330) inhibits glioblastoma growth in mice: an effect mediated by cyclin D1.

Phospho-Aspirin (MDC-22) Prevents Pancreatic Carcinogenesis in Mice.

Phospho-valproic acid inhibits pancreatic cancer growth in mice: enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles.

Alkaline Ceramidase 1 Protects Mice from Premature Hair Loss by Maintaining the Homeostasis of Hair Follicle Stem Cells.

Phosphosulindac is efficacious in an improved concanavalin A-based rabbit model of chronic dry eye disease.

[Corrigendum] Phospho‑valproic acid inhibits pancreatic cancer growth in mice: Enhanced efficacy by its formulation in poly‑(L)‑lactic acid‑poly(ethylene glycol) nanoparticles.

The Chemoprevention of Ovarian Cancer: the Need and the Options.

The ocular pharmacokinetics and biodistribution of phospho-sulindac (OXT-328) formulated in nanoparticles: Enhanced and targeted tissue drug delivery.

A New Rabbit Model of Chronic Dry Eye Disease Induced by Complete Surgical Dacryoadenectomy.

Phospho-valproic acid (MDC-1112) suppresses glioblastoma growth in preclinical models through the inhibition of STAT3 phosphorylation.

Correction: The Chemoprevention of Ovarian Cancer: the Need and the Options.

NSAID-induced corneal melt: Clinical importance, pathogenesis, and risk mitigation.

Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine.